

Open Veterinary Clinical Trial: DETERMINING PROGNOSIS IN CANINE SEPSIS BY BEDSIDE MEASUREMENT OF CELL-FREE DNA



Purpose: In people, increased plasma concentrations of cell-free DNA (cfDNA) have been demonstrated in burns, cancer, trauma, and sepsis. This cfDNA may originate from apoptotic cells or from neutrophil extracellular traps. Increased cfDNA concentrations are prognostic in febrile human ICU patients, and in people with bacteremia. Recently, we have identified cfDNA in the plasma of dogs with sepsis.

Aims: This study aims to investigate the utility of plasma cfDNA as a prognostic marker in canine sepsis and also to evaluate the accuracy of a point-of-care assay for bedside measurement of cfDNA in dogs.

Criteria required for admission: Any dog diagnosed with bacterial sepsis admitted to the CUHA will be eligible. Sepsis will be defined as evidence of systemic inflammation based on established criteria (heart rate, respiratory rate, temperature, leukocyte count), AND suspected or confirmed bacterial infection. A control population of healthy dogs will also be enrolled.

Client Compensation: \$200 of assays including CBC, chemistry, lactate, blood culture, blood pressure, and pulse oximetry.

Owner financial responsibility: Any additional tests or procedures will be the responsibility of the owner.

Enrollment period: Open

PRINCIPAL INVESTIGATORS

Dr. Robert Goggs

Dr. Jo-Annie Letendre

CONTACT INFORMATION

607-253-3060

[vet-research@cornell.edu](mailto:veter-research@cornell.edu)



Cornell University
College of Veterinary Medicine